Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
JAK1
REST API REST API
Homo sapiens
JAK1 is differentially expressed in 308 experiments: 127 organism parts: liver, ovary, ... (125 more);, 190 disease states: normal, prostate carcinoma, ... (188 more);, 115 cell types 376 cell lines 53 compound treatments and 80 other conditions.
Synonyms JAK1B, JAK1A, JTK3
Orthologs Q9YI47_CHICK (Gallus gallus)   Jak1 (Mus musculus)   jak1 (Danio rerio)   Jak1 (Rattus norvegicus)   Q4H3A3_CIOIN (Ciona intestinalis)   F1MQR0_BOVIN (Bos taurus)   PR2 (Drosophila melanogaster)   jak1 (Xenopus laevis)   Q6QHH1_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term endomembrane system, cytosol, response to antibiotic, protein binding, cytoskeleton, cytokine-mediated signaling pathway, cytoplasm, membrane, peptidyl-tyrosine phosphorylation, protein tyrosine kinase activity, ATP binding, nucleus, nucleotide binding, protein serine/threonine kinase activity, non-membrane spanning protein tyrosine kinase activity, protein kinase activity, intracellular protein kinase cascade, regulation of interferon-gamma-mediated signaling pathway, regulation of type I interferon-mediated signaling pathway, growth hormone receptor binding, enzyme linked receptor protein signaling pathway, protein phosphorylation, intracellular signal transduction, interferon-gamma-mediated signaling pathway, type I interferon-mediated signaling pathway
InterPro Term SH2, Prot_kinase_cat_dom, Band_41_domain, FERM_domain, Tyr_kinase_non-rcpt_Jak/Tyk2, Tyr_kinase_non-rcpt_Jak1, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession P23458
Search EB-eye ENSG00000162434
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-MTAB-62, ... (39 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639
BT474
2
E-MTAB-37, E-MEXP-440
HepG2
2
E-GEOD-21154, E-GEOD-7307
A549
2
E-GEOD-3202, E-GEOD-6013
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MCF7
2
E-GEOD-5258, E-MTAB-37
370 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-2822, ... (54 experiments)

Factor Value U/D Experiments
embryonic stem cell
3
E-MEXP-930, E-GEOD-2248, E-GEOD-26672
mesenchymal stem cell
2
E-GEOD-9894, E-GEOD-2248
human foreskin fibroblast
2
E-GEOD-18147, E-GEOD-18265
induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
109 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-MEXP-1121, E-TABM-15, E-GEOD-16363, ... (65 experiments)

Factor Value U/D Experiments
prostate carcinoma
1
5
E-GEOD-3868, E-MTAB-62, E-MTAB-37, E-MEXP-2034, E-TABM-26, ... (6 experiments)
septic shock
2
E-GEOD-8121, E-GEOD-9692
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
benign prostatic hyperplasia
2
E-MEXP-2034, E-GEOD-3868
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
colorectal adenocarcinoma
2
E-MTAB-62, E-AFMX-5
184 more value(s).


Compound treatment

studied in E-TABM-782, E-GEOD-697, E-GEOD-3720, E-TABM-868, E-MEXP-1958, ... (30 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-MEXP-1958, E-TABM-868, E-GEOD-3720
none
4
6
E-MEXP-1958, E-TABM-782, E-MEXP-1230, E-GEOD-412, E-TABM-868, ... (10 experiments)
ethanol
2
E-MEXP-2241, E-MEXP-1014
saline
1
E-GEOD-3026
poly(I:C)
1
E-MEXP-1230
RA
1
E-MEXP-2417
47 more value(s).


A rna yield

studied in E-TABM-325

Factor Value U/D Experiments
74.51
1
1
E-TABM-325


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-1140, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-7788, E-GEOD-22148, E-TABM-147, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (10 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-TABM-321, E-GEOD-18736, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-TABM-127, E-GEOD-20540, E-GEOD-20504, E-MEXP-1446, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (32 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (6 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84 ... (5 experiments)

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-1460, E-GEOD-17636, E-GEOD-923, ... (7 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-1676, E-MEXP-101, E-MEXP-1857, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-19743, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor size
studied in E-GEOD-3494

Vehicle
studied in E-GEOD-5258

Processing time: 0.336 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM